Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells

Area of Science:

• Immunology
• Gene Editing
• Cell Therapy

Background:

• CRISPR/Cas gene editing is revolutionizing immune cell therapies, particularly for natural killer (NK) cells, offering potent anti-tumor activity.
• Allogeneic, off-the-shelf NK cell therapies show promise in early trials, but CRISPR technology introduces risks like off-target edits and genomic instability.
• Multiplex editing and cytokine engineering (e.g., IL-15) enhance NK cell function and persistence but amplify safety concerns, necessitating rigorous evaluation.

Purpose of the Study:

• To review current safety assessment platforms for CRISPR-edited NK cells.
• To evaluate the suitability and limitations of various methods for detecting off-target events.
• To support the development of safe and effective gene editing workflows for NK cell therapies.

Main Methods:

• Summarizing predictive in silico tools for off-target analysis.
• Reviewing biochemical in vitro assays for detecting DNA damage and unintended modifications.
• Highlighting emerging cell-based systems for quantifying CRISPR-induced off-target events in primary NK cells.

Main Results:

• Various platforms exist to identify and quantify CRISPR-induced off-target events in gene-edited NK cells.
• In silico, in vitro, and cell-based assays offer different strengths and weaknesses for safety evaluation.
• The practical application of these methods in primary NK cells and multiplex editing strategies is discussed.

Conclusions:

• Robust safety assessments are crucial for CRISPR-edited NK cell therapies to ensure product integrity and patient safety.
• A combination of assessment platforms may be necessary to comprehensively evaluate risks associated with complex editing strategies.
• Continued development and validation of safety assessment tools are vital as NK cell therapies advance clinically.